PR-000608

PR-608
Clinical data
Other names	PR 000608
Identifiers
	IUPAC name 1-(4,4-Bis(4-fluorophenyl)butyl)-4-(2-hydroxy-3-phenylaminopropyl)piperazine;
CAS Number	143759-63-1;
PubChem CID	3072701;
ChemSpider	2332014;
ChEMBL	ChEMBL58192;
Chemical and physical data
Formula	C29H35F2N3
Molar mass	463.617 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CC(CNC4=CC=CC=C4)O;
	InChI InChI=1S/C29H35F2N3O/c30-25-12-8-23(9-13-25)29(24-10-14-26(31)15-11-24)7-4-16-33-17-19-34(20-18-33)22-28(35)21-32-27-5-2-1-3-6-27/h1-3,5-6,8-15,28-29,32,35H,4,7,16-22H2; Key:YIBOKAQCZWKXIM-UHFFFAOYSA-N;

PR-608 is a potent dopamine reuptake inhibitor related to vanoxerine. However, the GBR class of agents was known to be derived from diphenhydramine (or more specifically flunamine) as exemplified by S-350 and bears the distinctive benzhydryl ether functional group. PR-608 on the other hand belongs to the structurally distinct diphenylbutylpiperazine class of agents (related to the diphenylbutylpiperidine class). Other members of this class include amperozide, lidoflazine, difluanazine, FG5865 and FG-5893.

PR-608 has been shown in preclinical studies to inhibit dopamine uptake in the central nervous system and may have potential applications in neuropsychiatric and cardiovascular disorders.

The calcium channel blocking properties of PR-608 might make it useful as a cardiac stimulant for the treatment of heart disease or as a cerebral vasodilator. Alternative applications of this agent include for the treatment of psychostimulant addiction, neurodegenerative diseases including (but not limited to) Parkinson's disease, and as a treatment for depression. Since dopamine regulates the appetite, PR-608 might also find use for treating binge eating disorder (BED) as well as treating narcolepsy.